A Case for Strategic Investment
The ophthalmic therapeutics landscape is undergoing a transformative shift, driven by innovations that address unmet medical needs through non-invasive, precision-targeted solutions. Oculis Holding AG (OCS) stands at the forefront of this paradigm, leveraging its proprietary OPTIREACH® technology and a robust clinical pipeline to redefine treatment standards for diabetic macular edema (DME) and acute optic neuritis (AON). With a focus on pipeline differentiation and addressing high-unmet-need markets, Oculis presents a compelling case for strategic investment.
Pipeline Differentiation: OCS-01 for DME and OCS-05 for AON
Oculis’ lead candidate, OCS-01, is a high-concentration dexamethasone eye drop in Phase 3 trials for DME, a…
